Dendritic cell-based immunotherapy of prostate cancer

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 109-119

  Salgaller, M L ^a,b   Tjoa, B A ^a   Lodge, P A ^a,b   Ragde, H ^a   Kenny, G ^a   Boynton, A ^a,b   Murphy, G P ^a  

^a NORTHWEST HOSPITAL   (United States)

^b Northwest Biotherapeutics Inc   (United States)

Author keywords

Carcinoma; Human; Phase I trial; T cell; Therapy

Indexed keywords

CANCER VACCINE; HLA A2 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; ARTICLE; CONTROLLED STUDY; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; PROSTATE TUMOR;

DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030668321     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., DePlaen, E., van den Eynde, B., Kunth, A., and Boon, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma, Science, 254, 1643, 1991.
2. Gaugler, B., van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethé, B., Brasseur, F., and Boon, T., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, J. Exp. Med., 179, 921, 1994.
3. Boël, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J., Coulie, P., Boon, T., and van der Bruggen, P., BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes, Immunity, 2, 167, 1995.
4. van den Eynde, B., Peeters, O., De Backer., O., Gaugler, B., Lucas, S., and Boon, T., A new family of gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma, J. Exp. Med., 182, 689, 1995.
5. Brändle, D., Brasseur, F., Weynants, P., Boon, T., and van den Eynde, B., A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma, J. Exp. Med., 183, 2501, 1996.
6. Ressing, M. E., Sette, A., Brandt, R. M. P., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J. M., and Kast, W. M., Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A2*0201-binding peptides, J. Immunol., 154, 5934, 1995.
7. Chen, B. P., DeMars, R., and Sondel, P. M., Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant epstein-barr virus-transformed lymphoblastoid cell lines, Hum. Immunol., 18, 75, 1987.
8. Murphy, G. P., Ragde, H., Kenny, G., Barren, R., III, Erickson, S., Tjoa, B., Boynton, A., Holmes, E., Gilbaugh, J., and Douglas, T., Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients, Anticancer Res., 15, 1473, 1995.
9. Israeli, R. S., Powell, C. T., Corr, J. G., fair, W. R., and Heston, W. D. W., Expression of the prostate-specific membrane antigen, Cancer Res., 54, 1807, 1994.
10. Murphy, G. P., Tino, W. T., Holmes, E. H., Boynton, A. L., Erickson, S. J., Bowes, V. A., Barren, R. J., Tjoa, B. A., Misrock, S. L., Ragde, H., et al., Measurement of prostate-specific membrane antigen in the serum with a new antibody, Prostate, 28, 266, 1996.
11. Wright, J. G. L., Haley, C., Beckett, M. L., and Schellhammer, P. F., Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues, Urol. Oncol., 1, 18, 1995.
12. Coulie, P. G., Brichard, V., Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J., et al., A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med., 180, 35, 1994.
13. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A., Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc. Natl. Acad. Sci. U.S.A., 91, 3515, 1994.
14. Brichard, V., Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P. G., and Boon, T., The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma, J. Exp. Med., 178, 489, 1993.
15. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., and Singluff, Jr., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, 264, 716, 1994.
16. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection, Proc. Natl. Acad. Sci. U.S.A., 91, 6458, 1994.
17. Livingston, P. O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Jones Calves, M., Helling, F., Ritter, G., et al., Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside, J. Clin. Oncol., 12, 1036, 1994.
18. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S. A., A mutated beta-catenin gene encodes a melanomaspecific antigen recognized by tumor infiltrating lymphocytes, J. Exp. Med., 183, 1185, 1996.
19. ras protein by immunization in vivo with the oncogenic protein, J. Immunother., 14, 110, 1993.
20. Cheever, M. A., Chen, W., Disis, M. L., Takahashi, M., and Peace, D. J., T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl, Ann. NY Acad. Sci., 690, 101, 1993.
21. + cytotoxic T-cells, Cancer Res., 53, 3257, 1993.
22. Stuber, G., Leder, G. H., Storkus, W. J., Lotze, M. T., Modrow, S., Szekely, L., Wolf, H., Klein, E., Kärre, K., and Klein, G., Identification of wild-type and mutant p53 peptide binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay, Eur. J. Immunol., 24, 765, 1994.
23. Townsend, A. and Bodmer, H., Antigen recognition by class I-restricted T lymphocytes, A nnu. Rev. Immunol., 7, 601, 1989.
24. Germain, R. N. and Margulies, D. H., The biochemistry and cell biology of antigen processing and presentation, Annu. Rev. Immunol., 11, 403, 1993.
25. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G., and Rammensee, H., Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 290, 1991.
26. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A., Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules, Cell, 74, 929, 1993.
27. Engelhard, V. H., Structure of peptides associated with class I and class II MHC molecules, Annu. Rev. Immunol., 12, 181, 1994.
28. Lee, T. D. and Lee, J., Eds., Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals, in Distribution of HLA Antigens, Springer-Verlag, NY, 1990, 141-178.
29. Tjoa, B., Boynton, A., Kenny, G., Ragde, H., Misrock, S. L., and Murphy, G., Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity, Prostate, 28, 65, 1996.
30. Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W. D. W., Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, Cancer Res., 53, 227, 1993.
31. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P., Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients, Anticancer Res., 7, 927, 1987.
32. Austyn, J. M., New insights into the mobilization and phagocytic activity of dendritic cells [comment], J. Exp. Med., 183, 1287, 1996.
33. Steinman, R. M., The dendritic cell system and its role in immunogenicity, Annu. Rev. Immunol., 9, 271, 1991.
34. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A., and Carbone, D. P., Dendritric cells in antitumor immune responses, Cell. Immunol., 170, 1996.
35. Grabbe, S., Beissert, S., Schwarz, T., and Granstein, R. D., Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today, 16, 117, 1995.
36. + cytotoxic T lymphocytes by dendritic cells, J. Exp. Med., 166, 182, 1987.
37. + helper T cells, J. Exp. Med., 171, 1315, 1990.
38. Freudenthal, P. S. and Steinman, R. M., The distinct surface of human blood dendritic cells, as observed after an improved isolation method, Proc. Natl. Acad. Sci. U.S.A., 87, 7698, 1990.
39. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A., Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products, J. Exp. Med., 182, 389, 1995.
40. Tjoa, B., Erickson, S., Barren, R., III, Ragde, H., Kenny, G., Boynton, A., and Murphy, G., In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy, Prostate, 27, 63, 1995.
41. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A., Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen, Prostate, 29, 371, 1996.
42. Jones, R. C., Kelley, M., Gupta, R. K., Nizze, J. A., Yee, R., Leplatois, Z., Qi, K., Stern, S., and Morton, D. L., Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model, Ann. Surg. Oncol., 3, 437, 1996.
43. Morton, D. L., Foshag, L. J., and Hoon, D. S. B., Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine, Ann. Surg., 216, 463, 1992.
44. Thom, A., Alexander, H., And rich, M., Barker, W., Rosenberg, S., and Fraker, D., Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan, J. Clin. Oncol., 31, 264, 1995.